Comparative Pharmacology
Head-to-head clinical analysis: DROXIDOPA versus VASOSTRICT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROXIDOPA versus VASOSTRICT.
DROXIDOPA vs VASOSTRICT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Droxidopa is a synthetic precursor of norepinephrine that increases norepinephrine levels in the peripheral nervous system, thereby improving sympathetic tone and blood pressure regulation.
Vasopressin is a synthetic analogue of the antidiuretic hormone (ADH) that acts on V1 receptors (vascular smooth muscle) to cause vasoconstriction, and on V2 receptors (renal collecting ducts) to increase water reabsorption. At high doses used in vasodilatory shock, it primarily increases systemic vascular resistance via V1 receptor activation.
100-200 mg orally three times daily, with a maximum of 600 mg three times daily if needed.
0.01-0.03 units/min IV continuous infusion, titrate to effect. Maximum 0.1 units/min.
None Documented
None Documented
Clinical Note
moderateDroxidopa + Torasemide
"Droxidopa may increase the hypokalemic activities of Torasemide."
Clinical Note
moderateDroxidopa + Etacrynic acid
"Droxidopa may increase the hypokalemic activities of Etacrynic acid."
Clinical Note
moderateDroxidopa + Furosemide
"Droxidopa may increase the hypokalemic activities of Furosemide."
Clinical Note
moderateDroxidopa + Bumetanide
"Droxidopa may increase the hypokalemic activities of Bumetanide."
2–3 hours; terminal half-life approximately 2.5 hours, requiring 3–4 times daily dosing to maintain plasma levels.
Terminal elimination half-life is approximately 10–20 minutes, with clinical effect terminated rapidly by enzymatic degradation (catechol-O-methyltransferase and monoamine oxidase) in the liver and other tissues.
Renal: ~75% as unchanged drug and metabolites (including 3-O-methyldroxidopa and other conjugates); biliary/fecal: minimal (<5%).
Primarily renal (90–95% as inactive metabolites); minor biliary/fecal excretion (<5%).
Category C
Category C
Vasopressor
Vasopressor